Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance by rapid detection of pathogens and their potential resistance to antibiotics.
Through its Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com.
Pro Med Diagnostics is a Medical Diagnostic company specialising in the supply of laboratory based diagnostic products in the field of Fungal and Infectious diseases.
The founders of Pro Med Diagnostics, Neil and Anne Barker, have worked within the Medical Diagnostic field for all of their professional careers bringing a wealth of knowledge and experience to the organisation. Pro Med Diagnostics focuses on delivering an optimal level of customer support from the supply of quality products and service delivery.
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
Centivax raises USD45m to commercialise universal flu vaccine
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
INOVIO prices USD25m public offering
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Seegene launches STAgora infectious disease analytics platform
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results